It appears (based on the 10-K) that Jonathon Brown no longer has any direct operational involvement with the company since August 2014. Brown's LinkedIn profile describes him as an "entrepreneur", so maybe after getting FZMD established he is moving on to another venture. Perhaps his departure from the BOD is for purposes of bringing in an independent director or someone more actively involved.
Part of what interests me about FZMD is my hunch that the company will make acquisitions or joint ventures a part of its growth strategy going forward, and not rely just on organic growth. For some of the privately-held, medical-related companies that FZMD is (or will be) doing business with, FZMD might offer a relatively attractive avenue to go public.
Although that first merger with a pharmacy-related company was not completed at the time of the reverse merger, I still think that FZMD is very much interested in getting some exposure in that area. If I recall correctly, FZMD CEO Alan Meeker already has a personal direct/indirect ownership position in a compound pharmacy via his investment in World Health Industries (an investor in FZMD).
Back in 2013, Rusty Shelton made a presentation at the Physician Hospitals of America 13th Annual Conference. Included in that presentation was an organizational chart (page 20) which pretty much outlines the areas that Fuse Medical would like to get involved in. Retail/compound pharmacy, toxicology, durable/home medical equipment, DNA evaluation, etc......
Texas AmBioMed is a licensed distributor of Mimedx, according to the 2012 distribution agreement between AmBioMed and Fuse Medical. A copy of that agreement was filed in an 8-K on September 26, 2014 (page 6).....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.